Showing results (221-230 of 1,338) with videos related to

Sort By:
Pageof 134
Neuro-Oncology Advances|July 1, 2024
In vivo modeling recapitulates radiotherapy delivery and late-effect profile for childhood medulloblastomaJemma Castle, Gary Shaw, Dominic Weller, et al.
Neuro-Oncology Advances|July 22, 2024
Diffuse glioma molecular profiling with arterial spin labeling and dynamic susceptibility contrast perfusion MRI: A comparative studyYeva Prysiazhniuk, Andres Server, Henning Leske, et al.
Neuro-Oncology Advances|July 19, 2024
Early prognostication of overall survival for pediatric diffuse midline gliomas using MRI radiomics and machine learning: A two-center studyXinyang Liu, Zhifan Jiang, Holger R Roth, et al.
Neuro-Oncology Advances|July 18, 2024
Hemizygous deletion of cyclin-dependent kinase inhibitor 2A/B with p16 immuno-negative and methylthioadenosine phosphorylase retention predicts poor prognosis in IDH-mutant adult gliomaRyosuke Otsuji, Nobuhiro Hata, Hidetaka Yamamoto, et al.
Neuro-Oncology Advances|July 18, 2024
Differential gene expression underlying epileptogenicity in patients with gliomasArmin Mortazavi, Anas U Khan, Edwin Nieblas-Bedolla, et al.
Neuro-Oncology Advances|March 22, 2024
Fully automated MR-based virtual biopsy of primary CNS lymphomasVicky Parmar, Johannes Haubold, Luca Salhöfer, et al.
Neuro-Oncology Advances|September 14, 2023
Long-term outcomes with reduced-dose whole-brain radiotherapy and a stereotactic radiosurgery boost for primary central nervous system lymphomaBronwen E Foreman, Trey C Mullikin, Scott R Floyd, et al.
Neuro-Oncology Advances|August 9, 2023
Evaluating hematologic parameters in newly diagnosed and recurrent glioblastoma: Prognostic utility and clinical trial implications of myelosuppressionDavy Deng, Lubna Hammoudeh, Gilbert Youssef, et al.
Neuro-Oncology Advances|August 9, 2023
Change in volumetric tumor growth rate after cytotoxic therapy is predictive of overall survival in recurrent glioblastomaSonoko Oshima, Akifumi Hagiwara, Catalina Raymond, et al.
Neuro-Oncology Advances|August 9, 2023
A pilot phase Ib study to evaluate tadalafil to overcome immunosuppression during chemoradiotherapy for IDH-wild-type glioblastomaSubhajit Ghosh, Tanner M Johanns, Milan G Chheda, et al.
Pageof 134